Skip to main content
SpringerLink
Log in

Medullary Carcinoma of the Thyroid

Nuclear Medicine Imaging and Treatment

  • Chapter
Thyroid Cancer

  • 144 Accesses

Abstract

Early total thyroidectomy with resection of proven metastases is the treatment of choice for medullary thyroid cancer (MTC) (1–3). Therefore, localization of involved lymph nodes, soft tissue and bony metastases is important during the initial diagnostic workup and for recurrence surveillance. High-resolution ultrasound, computerized tomography (CT), and magnetic resonance imaging (MRI) have been used with some success (3–5). However, more advanced MTC is often characterized by distant metastases, involving lungs, liver and the skeletal system, making whole-body surveillance, of the type afforded by nuclear medicine techniques, the most useful for long-term follow-up. A variety of scintigraphic tracers, including 123I, 131I, 99mTc, DMSA, 201Tl, 131IMIBG, 99mTc MIBI, and 111In pentetreotide (Octreoscan) have been utilized for diagnosis and treatment of medullary thyroid cancer. Newer agents such as labeled antibodies may offer increased detection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wohllk N, Cote GJ, Evans DB, Goepfert H, Ordonez NG, Gagel RF. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol Metab Clin North Am 1996; 25: 1–26.

    Article  PubMed  CAS  Google Scholar 

  2. Simpson WJ, Palmer JA, Rosen IB, Mustard RA. Management of medullary carcinoma of the thyroid. Am J Surg 1982; 144: 420–422.

    Article  PubMed  CAS  Google Scholar 

  3. Sisson JC. Medical treatment of benign and malignant thyroid tumors. Endocrinol Metab Clin North Am 1989; 18: 359–387.

    PubMed  CAS  Google Scholar 

  4. Gorman B, Charboneau JW, James EM, et al. Medullary thyroid carcinoma: role of high-resolution US. Radiology 1987; 162: 147–150.

    PubMed  CAS  Google Scholar 

  5. Don U, Sautter-Bihl ML, Bihl. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. Semin Oncol 1994; 21: 42–45.

    Google Scholar 

  6. Krausz Y, Ish-Shalom S, DeJong RBJ, et al. Somatostatin-receptor imaging of medullary thyroid carcinoma. Clin Nucl Med 1994; 19: 416–421.

    Article  PubMed  CAS  Google Scholar 

  7. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76: 1413–1417.

    Article  PubMed  CAS  Google Scholar 

  8. Don U, Wurstlin S, Frank-Rave K, et al. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study. Horm Metab Res (Suppl) 1993; 27: 48–55.

    Google Scholar 

  9. Frank-Rave K, Bihl H, Don V, Buhr H, Ziegler R, Rave F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol 1995; 42: 31–37.

    Article  Google Scholar 

  10. Reubi JC, Chayvialle A, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatain content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567–573.

    PubMed  CAS  Google Scholar 

  11. Pacini F, Elisei R, Arelli S, Basolo F, Cola A, Pinchera A. Somatostatin in medullary thyroid cancer: in vitro and in vivo studies. Cancer 1989; 63: 1189–1195.

    Article  PubMed  CAS  Google Scholar 

  12. Miyauchi A, Endo K, Ohta H, et al. 99m-Tc(V)-Dimercaptosuccinic acid scintigraphy for medullary thyroid carcinoma. World J Surg 1986; 10: 640–645.

    Article  PubMed  CAS  Google Scholar 

  13. Skowsky WR, Wilf LH. Iodine 131 Metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid. Southern Med J 1991; 84: 636–641.

    PubMed  CAS  Google Scholar 

  14. Guerra UP, Pizzocaro C, Terzi A, et al. New tracers for the imaging of the medullary thyroid carcinoma. Nucl Med Commun 1989; 10: 285–295.

    Article  PubMed  CAS  Google Scholar 

  15. Clarke SEM, Lazarus CR, Wraight P, Sampson C, Maisey MN. Pentavalent [99m-Tc] DMSA, [131-I] MIBG, and [99m-Tc] MDP: an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 1988; 29: 33–38.

    PubMed  CAS  Google Scholar 

  16. Johnson DG, Coleman RE, McCook TA, Dale JK, Wells SA. Bone and liver images in medullary carcinoma of the thyroid gland: concise communication. J Nucl Med 1984; 25: 419–422.

    PubMed  CAS  Google Scholar 

  17. Hoefnagel CA, Delprat CC, Marcuse HR, deVijlder JJM. Role of thallium-201 total body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med 1986; 27: 1854–1857.

    PubMed  CAS  Google Scholar 

  18. Koizumi M, Yamada Y, Nomura E, et al. Scintigraphic detection of recurrence of medullary thyroid cancer. Ann Nucl Med 1995; 9: 101–104.

    Article  PubMed  CAS  Google Scholar 

  19. Lebouthillier G, Morais J, Picard M, Picard D, Chartrand R, D’Amour P. Tc-99m sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid. Clin Nucl Med 1993; 18: 657–661.

    Article  PubMed  CAS  Google Scholar 

  20. Shapiro B, Copp JE, Sisson JC, Exre PL, Wallis J, Beierwaltes WH. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1995; 26: 576–585.

    Google Scholar 

  21. Sone T, Fukunaga M, Otsuka N, et al. Metastatic medullary thyroid cancer: localization with iodine-131 metaiodobenzylguanidine. J Nucl Med 1985; 26: 604–608.

    PubMed  CAS  Google Scholar 

  22. Ansari AN, Siegel ME, DeQuattro V, Gazarian LH. Imaging of medullary thyroid carcinoma and hyperfunctioning adrenal medulla using iodine-131 metaiodobenzylguanidine. J Nucl Med 1986; 27: 1858–1860.

    PubMed  CAS  Google Scholar 

  23. Endo K, Shiomi K, Kasagi K, et al. Imaging of medullary thyroid cancer with 131-IMIBG. [Letter]. Lancet 1984; 2: 233.

    Article  PubMed  CAS  Google Scholar 

  24. Vuillez JP, Peltier P, Caravel JP, Chetanneau A, Saccavini JC, Chatal JF Immunoscintigraphy using 111-In-labelled F (ab’)2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab 1992; 74: 157–163.

    Article  PubMed  CAS  Google Scholar 

  25. O’Byrne KJ, Hamilton D, Robinson I, Sweeney E, Freyne PG, Cullen MJ. Imaging of medullary carcinoma of the thyroid using 111-In labelled anti-CEA monoclonal antibody fragments. Nucl Med Commun 1992; 13: 142–148.

    Article  PubMed  Google Scholar 

  26. Juweid M, Sharkey RM, Behr JM, et al. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Nucl Med 1996; 37 (suppl): 9 P.

    Google Scholar 

  27. Fritzsche H. Immunoscintigraphy in medullar thyroid cancer with Tc-99m-labelled monoclonal anti-CEA antibodies (BW431/26). Proc Int Thyroid Conf 1991; 10: 41.

    Google Scholar 

  28. Deftos LJ, Stein MF. Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma. J Clin Endocrinol Metab 1980; 50: 967–968.

    Article  PubMed  CAS  Google Scholar 

  29. Hellman DE, Kartchner M, Van Antwerp JD, Salmon SE, Patton DD, O’Mara R. Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1979; 48: 451–455.

    Article  PubMed  CAS  Google Scholar 

  30. McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 1985; 15: 132–153.

    Article  PubMed  CAS  Google Scholar 

  31. Fuzy M, Kornyei J. 131-I-MIBG therapy of widespread medullary thyroid carcinoma. [Abstract]. Eur J Nucl Med 1994; 21: 743.

    Google Scholar 

  32. Clarke SEM, Lazarus CR, Edwards S, et al. Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine. J Nucl Med 1987; 28: 1820–1825.

    PubMed  CAS  Google Scholar 

  33. Zanin DEA, van Dongen A, Hoefnagel CA, Bruning PF. Radioimmunoscintigraphy using iodine-131 anti-CEA monoclonal antibodies and thallium-201 scintigraphy in medullary thyroid carcinoma: a case report. J Nucl Med 1990; 31: 1854–1855.

    PubMed  CAS  Google Scholar 

  34. Juweid KM, Sharkey RM, Behr TM, et al. Treatment of medullary thyroid cancer (MTC) with radiolabelled monoclonal antibodies (MABs) against carcinoembryonic antigen (CEA). [Abstract]. J Nucl Med 1996; 37 (suppl): 243 P.

    Google Scholar 

  35. Waddington WA, Kettle AG, Heddle RM, Coakley AJ. Intraoperative use of indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med 1994; 2: 363–364.

    Article  Google Scholar 

Download references

Authors
  1. Diane Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerald Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Washington Hospital Center, Washington, DC, USA

    Leonard Wartofsky MD, MPH, MACP (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard) (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard)

  2. Uniformed Services University of Health Sciences, Washington, DC, USA

    Leonard Wartofsky MD, MPH, MACP (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard) (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard)

  3. George Washington University of Schools of Medicine, Washington, DC, USA

    Leonard Wartofsky MD, MPH, MACP (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard) (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sweeney, D., Johnston, G. (2000). Medullary Carcinoma of the Thyroid. In: Wartofsky, L. (eds) Thyroid Cancer. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-199-2_44

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-199-2_44

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6845-9

  • Online ISBN: 978-1-59259-199-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation